Search

EP-4735031-A2 - CODON OPTIMIZED PMCV SEQUENCES

EP4735031A2EP 4735031 A2EP4735031 A2EP 4735031A2EP-4735031-A2

Abstract

The present disclosure provides exemplary codon optimized nucleic acid sequences encoding Piscine Myocarditis Virus (PMCV). Expression vectors comprising one or more of the described codon optimized nucleic acids sequences are also provided.

Inventors

  • PATCH, Jared
  • MANE, Shrinivasrao, P.

Assignees

  • Intervet International B.V.

Dates

Publication Date
20260506
Application Date
20240626

Claims (20)

  1. 1. A codon optimized nucleic acid sequence comprising SEQ ID NO: 1.
  2. 2. A codon optimized nucleic acid sequence consisting essentially of SEQ ID NO:1.
  3. 3. A codon optimized nucleic acid sequence consisting of SEQ ID NO:1.
  4. 4. A codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO:1.
  5. 5. A codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:1.
  6. 6. A codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO:1.
  7. 7. A codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO:1.
  8. 8. A codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO:1.
  9. 9. A codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO:1.
  10. 10. A codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO:1.
  11. 11. A codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO:1 .
  12. 12. A codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO:1.
  13. 13. A codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO:1.
  14. 14. A codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO:1.
  15. 15. A codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO:1.
  16. 16. A codon optimized nucleic acid sequence comprising SEQ ID NO:2.
  17. 17. A codon optimized nucleic acid sequence consisting essentially of SEQ ID NO:2.
  18. 18. A codon optimized nucleic acid sequence consisting of SEQ ID NO:2.
  19. 19. A codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO:2.
  20. 20. A codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:2.

Description

CODON OPTIMIZED PMCV SEQUENCES CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Serial No. 63/523,476, filed on June 27, 2023, the entire disclosure of which is incorporated herein by reference. TECHNICAL FIELD The disclosure relates to sequences of Piscine Myocarditis Virus (PMCV) sequences that have been modified to comprise codons optimized for expression in cells. BACKGROUND AND SUMMARY OF THE INVENTION Cardiomyopathy syndrome (CMS) is an emerging disease of economic importance in salmon. In particular, the Piscine Myocarditis Virus (PMCV) has been identified as a causative link for CMS. PMCV is of large economic concern in the salmonid industry because it causes morbidity and mortality in adult fish that are nearly full grown and almost ready for harvest. PMCV encodes at least three major proteins: a capsid (ORF1), an RNA- dependent RNA polymerase (ORF2), and a structural protein of unknown function (ORF3) that may be involved in virus assembly or egress. However, attempts to propagate PMCV using in vitro cell culture systems have failed. As a result, traditional live, attenuated, and inactivated vaccine approaches have not yet materialized. Thus, there exists a need for a PMCV vaccine that utilizes DNA, RNA, or recombinant approaches for design, in particular those utilizing nucleic acid sequences that have been modified to comprise codons optimized for improved expression. Accordingly, the present disclosure, in one aspect, provides nucleic acid molecules (e.g., described in one aspect as sequences) encoding Piscine Myocarditis Virus (PMCV) protein(s). In one example, the nucleic acid sequences of the present disclosure have been modified to comprise codons optimized for improved expression in cells. DETAILED DESCRIPTION Various embodiments are described herein as follows. Illustrative aspects of the present disclosure include SEQ ID NO: 1. As described herein, SEQ ID NO: 1 corresponds to a codon optimized sequence for ORF_1 of PMCV. In an embodiment, a codon optimized nucleic acid sequence comprising SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence consisting of SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO: 1 is provided. Illustrative aspects of the present disclosure include SEQ ID NO: 2. As described herein, SEQ ID NO: 2 corresponds to a codon optimized sequence for ORF_3 of PMCV. In an embodiment, a codon optimized nucleic acid sequence comprising SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence consisting of SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon